IL-33 and IL-37 play a counteractive role in regulating inflammation involving the activation of mast cells in chronic rhinosinusitis with a differential expression in allergy and sinusitis compared to polyp, which further suggests IL-33 and IL-37 as novel therapeutic targets, and the findings of this study support this [88]. This evidence concerns the gene IL37 and polyp.